FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

vasimigton, b.c. 20045

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average b	ourden							

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Ho Carole</u>						2. Issuer Name <b>and</b> Ticker or Trading Symbol  Denali Therapeutics Inc. [ DNLI ]								(Ched	k all app Dired	olicable)		erson(s) to Is 10% C Other	
(Last) (First) (Middle) C/O DENALI THERAPEUTICS INC. 151 OYSTER POINT BOULEVARD, SECOND FLOOR					3. Date of Earliest Transaction (Month/Day/Year) 08/29/2018								X Officer (give title Officer Specify below)  Chief Medical Officer						
(Street) SOUTH FRANCI (City)	sco C.		94080 Zip)		4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Ind Line) X	′					
				on-Deriv	ative	Sec	uritie	s Ac	quired	d, Di	sposed o	f, or B	enefic	cially	Owne	ed			
1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/				tion	on 2A. Deemed Execution Date,		3. 4. Secu		4. Securities Disposed O	s Acquire	ed (A) or	5. Amo Securit Benefic Owned		unt of ies cially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
					Code	v	Amount	(A) or (D)	Price			ported Insaction(s) str. 3 and 4)			(Instr. 4)				
Common	Stock														40	5,875		<b>D</b> <sup>(1)</sup>	
Common	Stock														25	5,000			See footnote <sup>(2)</sup>
Common Stock 08/2			08/29/2	2018				<b>S</b> <sup>(3)</sup>		17,500	D	\$18.	.04(4)	4 <sup>(4)</sup> 218,390				See footnote <sup>(5)</sup>	
		Та	ıble II								osed of, convertib				wned				
1. Title of Derivative Security (Instr. 3)	rivative Conversion Date Execution Date, curity or Exercise (Month/Day/Year) if any		4. Transa Code ( 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)  Date Expiration Exercisable Date			7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)  Amoun or Numbe of Title Shares		nt er		9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	у	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		

## Explanation of Responses:

- 1. The shares are held of record by Carole Ho and Rajat Rohatgi.
- 2. The shares are held of record by the Rohatgi-Ho Irrevocable GST Trust, for which Reporting Person serves as trustee.
- 3. The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
- 4. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from \$18.00 to \$18.20 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- 5. The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee.

## Remarks:

<u>/s/ Tyler Nielsen, by power of attorney</u>

08/31/2018

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.